Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$17.87MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey S. Hackman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Beta
- 1.10
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 3.81
Financials
Revenue
$17.87M+10414.1%Net Income
$1.97MEBITDA
$1.76MFree Cash Flow
$50.0KEPS (diluted)
$0.05Shares Outstanding (diluted)
36.43M+167.0%Operating Expenses
$15.42MCash & Debt
$41.25MReturn of Capital
$0.00Revenue by Segment (annual)
$170.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.64M | $-9.74M | $-0.36 |
| 2024 | $47.54M | $-436.0K | $-0.02 |
| 2023 | $21.25M | $-16.05M | $-0.60 |
| 2022 | $1.53M | $-23.71M | $-0.95 |
| 2021 | $0.00 | $-17.35M | $-0.67 |
| 2020 | $170.0K | $-18.11M | $-0.76 |
| 2019 | $0.00 | $-13.07M | $-0.63 |
| 2018 | $0.00 | $-9.89M | $-0.52 |
| 2017 | $0.00 | $-7.05M | $-0.47 |
| 2016 | $0.00 | $-2.79M | $-0.22 |
| 2015 | $0.00 | $-659.0K | $-0.06 |
| 2014 | $0.00 | $-2.18M | $-0.22 |
| 2013 | $0.00 | $1.84M | $0.19 |
| 2012 | $0.00 | $-5.16M | $-0.63 |
Valuation
FENChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-80.43%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·19d ago·Negative
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Adherex Technologies Q2 Earnings Call Highlights Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
View source ↗ - Newszacks.com·56d ago·Neutral
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $0.09 per share
Typical surprise +66.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$0.05 vs $0.02beat
- Thu, May 14$0.01 vs $-0.02beat
- Tue, Mar 24$-0.17 vs $0.03miss
- Thu, Nov 13$-0.02 vs $-0.08beat
- Thu, Aug 14$-0.11 vs $-0.06miss
- Tue, May 13$-0.04 vs $-0.12beat
Estimates and results for FENC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FENC officers and directors.
- Bought
- —
- Sold
- $2.0m
0 trades
12 trades
- Brughera Marco Mariasold
- Raykov Rostysold
- Sayad Pierre Sargissold
- Andrade Robertsold
- Raykov Rostysold
- Raykov Rostysold
- Raykov Rostysold
- Rallis Chris Asold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FENC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.